Business
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the first quarter ended March 31, 2026.
About this update from Ideaya Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2 2026","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical updates from Phase 2 OptimUM-01 trial in HLA*A2-positive mUM, Phase 2 OptimUM-09 in neoadjuvant primary UM and Phase 1/2 trials with IDE849 (DLL3 TOP1 ADC) and IDE034 (B7H3/PTK7 bispecific TOP1 ADC) planned for H2 2026","length":227,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiation of registrational trial for IDE849 monotherapy in DLL3-positive solid tumors planned by year-end 2026; Phase 1 combination cohort of IDE892 (PRMT5) + IDE397 (MAT2A) in MTAP-deleted cancers to begin in mid-2026","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"~$973 million of cash, cash equivalents, and marketable securities as of March 31, 2026; current cash runway guidance into 2030 remains unchanged","length":145,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":891,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the first quarter ended March 31, 2026.","length":252,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":261,"url":"https://media.zenfs.com/en/prnewswire.com/b53b2c167935532309987db78b249c89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9TYoum0K3OycBPFggMPOXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2MA--/https://media.zenfs.com/en/prnewswire.com/b53b2c167935532309987db78b249c89","width":400,"height":261}},"href":"https://mma.prnewswire.com/media/820568/IDEAYA_v2_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This was a transformational quarter for IDEAYA, with positive topline results from the OptimUM-02 reg...